These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17390380)

  • 21. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
    Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
    Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolerance to factor VIII inhibitors in hemophilia A patients: a French twist.
    Pascual V; Capra JD
    J Clin Invest; 1996 Mar; 97(6):1357-8. PubMed ID: 8617864
    [No Abstract]   [Full Text] [Related]  

  • 23. Identification of novel peptide agonists from a random peptide library for a 5-oxo-ETE receptor, a receptor for bioactive lipids.
    Sasaki Y; Tsujii T; Takeda S; Obinata H; Izumi T; Yamada K; Katakai R
    J Pept Sci; 2008 Dec; 14(12):1251-8. PubMed ID: 18752253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Circulating anticoagulants against coagulation factors with special reference to anti-factor VIII:C].
    Aznar JA
    Sangre (Barc); 1985; 30(4-C):813-8. PubMed ID: 3937252
    [No Abstract]   [Full Text] [Related]  

  • 25. Identification of a ligand for IgG-Fc derived from a soluble peptide library based on fusion proteins secreted by S. cerevisiae.
    Mersich C; Billes W; Jungbauer A
    Biotechnol J; 2007 Jun; 2(6):672-7. PubMed ID: 17492714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.
    Wootla B; Mahendra A; Dimitrov JD; Friboulet A; Borel-Derlon A; Rao DN; Uda T; Borg JY; Bayry J; Kaveri SV; Lacroix-Desmazes S
    FEBS Lett; 2009 Aug; 583(15):2565-72. PubMed ID: 19595998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G.
    Wootla B; Dasgupta S; Mallet V; Kazatchkine MD; Nagaraja V; Friboulet A; Kaveri SV; Lacroix-Desmazes S
    Blood Coagul Fibrinolysis; 2006 Jun; 17(4):229-34. PubMed ID: 16651863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Studies on the human factor VIII (anti-hemophilic factor). II. Properties of human and rabbit antibodies against human factor VIII (author's transl)].
    Niiya K
    Nihon Ketsueki Gakkai Zasshi; 1978 Jun; 41(3):543-52. PubMed ID: 567921
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunology of factor VIII inhibitors.
    Saint-Remy JM
    Semin Thromb Hemost; 2002 Jun; 28(3):265-8. PubMed ID: 12098086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. De novo identification of binding sequences for antibody replacement molecules.
    Quirk S; Zhong S; Hernandez R
    Proteins; 2009 Aug; 76(3):693-705. PubMed ID: 19274738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
    Meli G; Visintin M; Cannistraci I; Cattaneo A
    J Mol Biol; 2009 Apr; 387(3):584-606. PubMed ID: 19361429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of mRNA-display-based selections using synthetic peptide and natural protein libraries.
    Huang BC; Liu R
    Biochemistry; 2007 Sep; 46(35):10102-12. PubMed ID: 17685586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering antibodies by yeast display.
    Boder ET; Raeeszadeh-Sarmazdeh M; Price JV
    Arch Biochem Biophys; 2012 Oct; 526(2):99-106. PubMed ID: 22450168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitor development.
    Astermark J; Lacroix-Desmazes S; Reding MT
    Haemophilia; 2008 Jul; 14 Suppl 3():36-42. PubMed ID: 18510520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitor development in one patient and laboratory discrepancies in several families with both mild haemophilia and Arg531Cys mutation.
    Cid AR; Casaña P; Cabrera N; Haya S; Cortina V; Aznar JA
    Haemophilia; 2007 Mar; 13(2):206-8. PubMed ID: 17286776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antagonists of Hsp16.3, a low-molecular-weight mycobacterial chaperone and virulence factor, derived from phage-displayed peptide libraries.
    Saha A; Sharma A; Dhar A; Bhattacharyya B; Roy S; Das Gupta SK
    Appl Environ Microbiol; 2005 Nov; 71(11):7334-44. PubMed ID: 16269776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening of ACE-inhibitory peptides from a random peptide-displayed phage library using ACE-coupled liposomes.
    Kumada Y; Hashimoto N; Hasan F; Terashima M; Nakanishi K; Jungbauer A; Katoh S
    J Biotechnol; 2007 Aug; 131(2):144-9. PubMed ID: 17658644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of VWF in the immunogenicity of FVIII.
    Lacroix-Desmazes S; Repessé Y; Kaveri SV; Dasgupta S
    Thromb Res; 2008; 122 Suppl 2():S3-6. PubMed ID: 18549909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-neutralizing anti-FVIII antibodies: different binding specificity to different recombinant FVIII concentrates.
    Vincent AM; Lillicrap D; Boulanger A; Meilleur C; Amesse C; St-Louis J; Rivard GE
    Haemophilia; 2009 Jan; 15(1):374-6. PubMed ID: 19149862
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.